Public Profile

Affymax, Inc.

Affymax, Inc., a prominent biotechnology company headquartered in the United States, has been at the forefront of innovative therapies since its founding in 1997. Specialising in the development of novel treatments for patients with chronic kidney disease, Affymax has made significant strides in the biopharmaceutical industry, particularly with its flagship product, Omontys (peginesatide), which offers a unique approach to anaemia management. With a focus on enhancing patient outcomes, Affymax has established a strong market position through its commitment to research and development. The company’s dedication to advancing healthcare solutions has garnered recognition within the industry, marking it as a key player in the biotechnology sector. As it continues to evolve, Affymax remains dedicated to delivering transformative therapies that address unmet medical needs.

DitchCarbon Score

How does Affymax, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

18

Industry Average

Mean score of companies in the Household Employment industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

20

Industry Benchmark

Affymax, Inc.'s score of 18 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.

33%

Let us know if this data was useful to you

Affymax, Inc.'s reported carbon emissions

Affymax, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is challenging to assess their carbon footprint or evaluate their climate commitments. The absence of documented reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the industry increasingly prioritises sustainability, it is essential for Affymax to establish clear climate goals and transparency in emissions reporting to align with global climate standards and expectations.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Affymax, Inc.'s primary industry is Private households with employed persons (95), which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Affymax, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Affymax, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Nautilus Biotech S.A.

FR
Health and social work services (85)
Updated about 5 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers